Achieve Life Sciences (ACHV) Projected to Post Earnings on Thursday

Achieve Life Sciences (NASDAQ:ACHV) is anticipated to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Achieve Life Sciences (NASDAQ:ACHV) last issued its quarterly earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.06). On average, analysts expect Achieve Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Achieve Life Sciences Stock Down 3.7 %

NASDAQ ACHV opened at $2.86 on Wednesday. The business has a fifty day moving average price of $3.08 and a 200 day moving average price of $3.93. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. The company has a market cap of $99.20 million, a P/E ratio of -2.53 and a beta of 1.67. Achieve Life Sciences has a one year low of $2.51 and a one year high of $5.59.

Insider Activity

In related news, CFO Mark K. Oki bought 10,000 shares of the business’s stock in a transaction on Monday, March 17th. The stock was acquired at an average cost of $2.89 per share, with a total value of $28,900.00. Following the purchase, the chief financial officer now directly owns 10,000 shares of the company’s stock, valued at $28,900. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 2.00% of the company’s stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.